Batch-Documented
HPLC-Verified
Independent Assay
Same Reorder Price
GLPs · TRIPLE GLP-1/GIP/GLUCAGON AGONIST
RT3 - LY3437943 30 mg
Lyophilized vial · 39 AA
— Vial size
RT3 - LY3437943 — independently assayed, batch-tested, and shipped from our fulfillment facility in San Antonio. Released only after an independent laboratory returns its results for the batch.
Per vial
Select your pack size
SingleShips within 48 hours from San Antonio
UPS Ground · tracked + insured · released after independent lab testing
- Purity Guarantee. If a batch fails our ≥99% HPLC standard, full refund + replacement.
- Batch certificate in the COA library, anytime, free
- Same reorder price — forever, no upcharge
$169.99
Single
— About this compound
RT3 - LY3437943.
Class · Triple agonist at GIP, GLP-1, and glucagon receptors (synthetic peptide)
Origin. Developed by Eli Lilly. First publicly characterized by Coskun et al. in 2022 as the next-generation evolution of the dual-incretin concept embodied in tirzepatide.
Retatrutide (research code LY3437943) is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation.
The compound is currently in late-stage clinical investigation for obesity and type 2 diabetes. Public literature is concentrated in Phase 1–2 trial reports and preclinical pharmacology.
— Common research applications
- Triple-incretin pharmacology
- Energy expenditure research
- Comparative incretin-agonist studies
- Metabolic flux models
— Mechanism
How it's been studied.
Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models.
Mechanism descriptions reflect findings reported in the preclinical and basic-research literature. They are not clinical conclusions and not statements of therapeutic effect.
— The Chemistry
The numbers, plainly.
CAS
2381089-83-2
Molecular weight
5419 Da
Formula
—
Sequence
—
Format
Lyophilized powder
Vial dose
30 mg
Purity (HPLC)
≥99%
Amino acids
39
Half-life
~6 days (early clinical pharmacokinetic reports).
Solubility
Reconstitutes in bacteriostatic water.
View lab results for RT3 - LY3437943 → or search by compound.
— Why Merit
The supplier difference.
How Merit compares to the two alternatives most research buyers consider for RT3 - LY3437943.
Comparison reflects published facility status and standard industry practice. Compounding pharmacy availability of research peptides varies by jurisdiction.
— How it's made
From compound to your shelf.
Every Merit batch follows the same documented path. Five steps, every one verifiable.
- 01
Sourcing
Compound starts as a research-grade API.
Active pharmaceutical ingredient sourced from FDA-registered manufacturers. Identity confirmed against reference standard before any compounding begins.
- API from FDA-registered manufacturers
- Identity verified against reference standard
- Chain of custody documented
- 02
Compounding
Sterile-filled in a US cleanroom.
Lyophilized in a cleanroom at our US facility. The powder format gives ≥24 months sealed stability — no cold-chain shipping required.
- ISO-certified US facility
- ISO-certified manufacturing process
- Lyophilized powder for transit stability
- 03
Verification
Every batch HPLC-tested.
Reverse-phase HPLC-UV (UV/MS for higher-MW peptides) confirms identity and purity for every batch before it leaves the lab. The chromatogram is archived.
- Reverse-phase HPLC, per-batch
- ≥99% purity floor — every batch
- Chromatogram archived for every batch
- 04
Release
The batch is released against an independent assay.
No batch ships until an independent laboratory has returned its identity and purity results and the certificate is published in the COA library.
- Independent laboratory on every batch
- Certificate published before sale
- Every certificate is in the public COA library
- 05
Dispatch
Ships from San Antonio in 48 hours.
Sealed vials with a QR code on the label that opens the COA library. Order before 2pm CT Monday–Thursday for same-day dispatch. UPS Ground, tracked + insured.
- 48hr dispatch from San Antonio, TX
- QR code on every vial label
- UPS Ground, tracked + insured
Every step above can be verified for any specific batch by emailing rx@meritsciences.com with your order number.
— Research references
The published record.
Peer-reviewed work cited in the public scientific literature. Links resolve to PubMed or the publisher of record.
- 01
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Coskun T, Urva S, Roell WC, et al. · Cell Metabolism · 2022
- 02
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine · 2023
- 03
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Rosenstock J, Frias J, Jastreboff AM, et al. · The Lancet · 2023
Inclusion of a reference does not constitute a clinical claim or recommendation.
— The Batch Note
Triple-agonist — newer than Tirzepatide. Limited literature but increasing research interest.
Merit Sciences Lab Team
Independently assayed · ISO-certified US facility · Ships from San Antonio, TX
— Common Questions
Got questions.
What is RT3 - LY3437943?+
Retatrutide (research code LY3437943) is a single-molecule triple agonist that activates the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The triple-incretin pharmacology represents an attempt to combine the insulin-sensitizing and appetite-modulating effects of GLP-1/GIP agonism with the energy-expenditure effects of glucagon receptor activation.
How does RT3 - LY3437943 work?+
Picomolar-affinity agonist at GIP, GLP-1, and glucagon receptors. The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models.
What class of compound is RT3 - LY3437943?+
RT3 - LY3437943 is classified as triple agonist at GIP, GLP-1, and glucagon receptors (synthetic peptide).
What is the reported half-life of RT3 - LY3437943?+
~6 days (early clinical pharmacokinetic reports).
Why does Merit ship lyophilized?+
Lyophilized format gives ≥24 months sealed stability at -20°C — significantly longer than pre-reconstituted, which has a 30-day shelf life once in solution. You reconstitute at the moment of use, when potency is at its peak.
How do I check the certificate for my batch?+
The QR code on every vial opens our COA library. Search by compound to find the certificate for the batch currently shipping. No account and no request form, and the library keeps every certificate we have released.
What does "independently assayed" actually mean?+
Every batch is tested by a laboratory independent of the facility that made it, and the certificate is published before the batch is listed. You read the same identity and purity figures we do — that's what separates Merit from a reseller catalog.
Will my bank flag this purchase?+
Statements show as Merit Sciences LLC. Standard merchant descriptor — does not trigger category-code flags. All major cards and PayPal accepted at checkout.
How fast does it ship?+
48 hours from order to dispatch, Monday through Thursday. UPS Ground, tracked + insured. From San Antonio, TX, most US addresses receive within 3-5 business days.
— Talk to a Pharmacologist
Question we didn't answer?
Our team answers compound questions, batch questions, and protocol questions — same business day. No bots, no tickets.
Email the team →— Same Family
